Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial

Published: Friday, November 15, 2013
Last Updated: Friday, November 15, 2013
Bookmark and Share
Sample collection for the study is due to commence in April 2014 and be completed by the end of 2015.

VolitionRx Limited has announced an increase of 55% (from 6,000 to 11,000) in the number of prospective blood samples to be included in its forthcoming colorectal cancer clinical trial at no additional cost beyond the $1.85 million already announced.

The randomized, blinded study is designed to evaluate the validity of VolitionRx’s proprietary NuQ® panel as a first-step screening tool for colorectal cancer.

Sample collection for this prospective study, which is jointly sponsored by VolitionRx and the University of Copenhagen, is due to commence in April 2014 and be completed by the end of 2015.

With the additional blood samples, 8,000 individuals receiving a positive faecal immunological testing (FIT) result and 3,000 individuals receiving a negative FIT result as part of the Danish national screening programme will now be tested using Volition’s NuQ assay panel.

The results will be verified by colonoscopy. Notably, the Danish team is collecting up to 120 data points for each individual included in the trial (e.g. age, gender, other diseases). This will provide an extremely powerful tool in understanding how different diseases and conditions interrelate with colorectal cancer.

The additional blood samples will be collected by Professor Hans Jørgen Nielsen, Professor of Surgical Oncology at the Department of Surgical Gastroenterology at Hvidovre Hospital, part of the University of Copenhagen, and collaborators at 7 additional Danish hospital departments.

Speaking about the expansion, Professor Nielsen says: “Our decision to provide Volition with these extra samples was driven by the promising interim data from other NuQ trials. This expansion is significant as we will be able to make even stronger conclusions about both the accuracy of VolitionRx’s NuQ blood test and the risk factors of colorectal cancer. We also now have the possibility to re-confirm the results of symptom-free individuals who are undergoing screening.”

Dr Jake Micallef, Chief Scientific Officer of VolitionRx, adds: “Professor Nielsen and collaborators' collection of extensive blood samples provides the opportunity to identify and validate other molecules and genetic components associated with the growth, invasion and dissemination processes of colorectal cancer. We will now have further data to analyze in relation to colonoscopy findings, to demonstrate the performance of a simple NuQ blood test to diagnose colorectal cancer at an early stage in a non-invasive way. The 11,000 prospective samples are in addition to the already collected 4,800 retrospective symptomatic samples for a combined 16,000 individuals. We have received the first 1,000 samples from the retrospective trial we are carrying out in conjunction with Hvidovre Hospital, and will begin the analysis this year.”

In addition to analyzing the 16,000 Danish individuals, Volition is carrying out the following trials:
• 3 ongoing multi-cancer studies at University Hospital in Bonn, Germany, including an 800 patient retrospective study and a 2,000 patient prospective study that involves patients with the 20 most prevalent cancers
• a 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium.

Data from these trials will be used to apply for a CE mark for a colorectal cancer test, and will also be submitted to the FDA.

Colorectal cancer is the third most prevalent cancer worldwide, after lung and breast cancers, with approximately 1.24 million new cases diagnosed each year. In the United States alone, 136,717 people were diagnosed with colorectal cancer in 2009, with 51,848 dying from the disease that year.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!